A new prenatal roadmap could soon help clinicians place endotracheal tubes (ETTs) more precisely in the tiniest preterm newborns. In infants with birth weights under 500 g, even small positioning errors during intubation can increase the risk of life‑threatening complications, including inadequate ventilation or airway trauma. Researchers say their approach uses measurements taken before birth—capturing the baby’s anatomy while it is still developing in utero.

The study focuses on predicting the optimal ETT depth rather than relying solely on standard postnatal formulas. Using prenatal biometry, investigators model how fetal growth and structural proportions relate to the distance from the mouth to the trachea. The goal is to translate ultrasound-derived anatomical signals into a practical estimate that can guide clinicians at the bedside.

Technically, the model links prenatal measurements to the anticipated airway dimensions at delivery. This requires defining which biometric inputs best correlate with the final tube placement target, then training a predictive framework to output a recommended insertion depth for extremely low birth weight infants. By emphasizing prenatal inputs, the method aims to reduce uncertainty that can arise from day-to-day postnatal changes.

Importantly, the research targets a subgroup with particularly high vulnerability. Infants below 500 g are at increased risk because their airway structures are extremely small and intubation margins are narrow. In this context, individualized prediction could improve consistency compared with one-size-fits-all guidelines.

If validated in larger clinical settings, the prenatal model could be integrated into obstetric and neonatal workflows. After routine prenatal ultrasound assessments, clinicians would generate an ETT depth estimate ahead of delivery, supporting more confident planning for immediate respiratory care.

The findings also highlight a broader trend in perinatal medicine: using quantitative prenatal data to optimize invasive procedures. Instead of reacting after intubation placement, the strategy moves decision-making earlier—toward anticipation, personalization, and safety.

Overall, the work suggests that prenatal biometry can carry actionable information for airway management. The team frames the approach as a step toward more precise, data-driven neonatal resuscitation and ventilation strategies for the smallest patients.

The study, published in Journal of Perinatology, is available under DOI: 10.1038/s41372-026-02851-2.

Subject of Research: Prenatal biometry-based prediction of optimal ETT depth
Article Title: Prenatal biometry-based prediction of optimal endotracheal tube depth in infants with a birth weight less than 500 g.
Article References: Yoo, K., Kim, S.H., Park, J. et al. J Perinatol (2026). https://doi.org/10.1038/s41372-026-02851-2
Image Credits: AI Generated
DOI: 10.1038/s41372-026-02851-2
Keywords:

Short-chain fatty acids (SCFAs)—especially acetate, propionate, and butyrate—are produced when gut microbes ferment carbohydrates that the human body cannot digest. Over the past decade, these small molecules have moved beyond being viewed as simple fuel. Instead, they are now recognized as signalling messengers that help tune metabolism, shape immune responses, and support physiological balance across organs. A new review in Nature Metabolism brings together scattered findings to clarify how SCFAs are made, how they are processed in the body, and why they matter for health.

The article emphasizes that SCFA production is not uniform. It depends on which microbial communities inhabit the gut, which dietary substrates reach the colon, and how microbes share resources through cross-feeding. When multiple bacterial species coordinate, fermentation pathways can shift, increasing the output of particular SCFAs. In that way, the “hardware” of the microbiome and the “inputs” provided by diet jointly determine the chemical signals generated in the intestine.

After their formation, SCFAs are handled by host tissues through absorption and further metabolic conversion. The review highlights that acetate, propionate, and butyrate can influence local and systemic physiology, helping link intestinal chemistry to whole-body regulation. Their effects are therefore both immediate—through signalling pathways—and longer-lasting—through changes in gene regulation.

Mechanistically, the authors focus on receptor-mediated communication. SCFAs activate specific receptors on immune and metabolic cells, altering inflammatory tone and metabolic signalling. This receptor layer helps explain how intestinal events can reverberate in distant tissues that rely on tightly controlled energy and immune states.

Beyond receptors, SCFAs also affect epigenetics. By influencing chromatin-modifying enzymes and related regulatory networks, they can change how genes are expressed without altering DNA sequence. Such effects provide a plausible bridge between diet–microbiome interactions and sustained shifts in health trajectories.

The review further surveys tissue-specific outcomes, from effects on gut barrier function to immune regulation and metabolic homeostasis. Importantly, this heterogeneity helps reconcile why SCFAs sometimes show protective associations while other contexts yield mixed results—differences in dose, timing, microbial ecology, and host physiology can all matter.

When the evidence is assembled, the paper argues that SCFAs are strongly implicated in metabolic health and disease risk. Conditions such as obesity, insulin dysregulation, and inflammatory disorders have been linked to altered SCFA profiles, though causality remains an active area of investigation. The authors also discuss the limitations of current studies, including differences in measurement methods and confounding dietary factors.

Finally, the review evaluates translational opportunities. Rather than treating SCFAs as isolated supplements, it frames dietary and therapeutic strategies around pathways that enhance beneficial SCFA production or mimic their downstream effects. With low fibre intake becoming a public health concern worldwide, the work positions SCFAs as a key biological rationale for improving diet quality.

Overall, this Nature Metabolism review synthesizes what is known—and what is still uncertain—about SCFAs as central mediators between gut microbes and host biology. It suggests that targeting microbial fermentation and SCFA signalling could become a practical lever for metabolic disease prevention.

Subject of Research: Gut microbiota–derived short-chain fatty acids and their physiological roles
Article Title: Short-chain fatty acids
Article References: Dagbasi, A., Cai, M., Hirdaramani, A. et al. Short-chain fatty acids. Nat Metab (2026). https://doi.org/10.1038/s42255-026-01579-9
DOI: https://doi.org/10.1038/s42255-026-01579-9
Image Credits: AI Generated

Age-related remodeling of the immune system leaves older adults increasingly susceptible to sudden infections and cancer, while also promoting chronic, misdirected inflammation and impaired wound repair. These effects help drive a wide spectrum of long-term diseases. Yet despite rapid progress in immunology and gerontology, key mechanistic links—how specific immune-cell programs degrade over time and how that degradation shapes early response decisions—remain incompletely understood.

A major obstacle has been the limited availability of immune-aging models that are both predictive and experimentally tractable. Conventional in vitro systems often fail to capture the tissue context, cellular crosstalk, and microenvironmental cues that govern when and how immune responses ignite. As a result, “aging phenotypes” can be difficult to reproduce across laboratories and difficult to connect to causal pathways.

In a 2026 Nature Aging discussion, Nikolich and colleagues argue that the field needs a shift from descriptive comparisons toward engineered, mechanistically grounded platforms. They propose multidisciplinary strategies spanning immunology, gerontology, and engineering to interrogate immune aging at the point of initiation—when innate sensors, tissue barriers, and early signaling networks collectively determine the trajectory of downstream immunity.

The authors highlight drug delivery technologies as a route to more precise interventions. By tuning where, when, and at what dose immunomodulatory agents act, researchers could better test how age-altered signaling thresholds change the balance between protective responses and harmful inflammation.

They also emphasize extracellular matrix (ECM) and biomaterials, noting that aging reshapes the physical and biochemical scaffold surrounding immune cells. Biomaterials that recapitulate age-associated stiffness, ligand density, and degradation dynamics could reveal how microenvironmental cues reprogram immune recruitment, activation, and effector function.

Microphysiological systems and organoid-like models are presented as complementary engines for causality. These platforms can integrate multiple cell types, enable controlled perturbations, and better mimic tissue architecture than traditional culture formats.

Together, these approaches aim to deliver validated in vitro tools for immune-aging research—tools designed not only to measure differences, but to reproduce them reliably and connect them to specific upstream drivers.

The ultimate ambition is precision diagnostics and therapies that can “reprogram and rejuvenate” immune function in older adults, extending both lifespan and healthspan. By targeting immune-response initiation with engineered models, the field may finally bridge the gap between observational aging biology and interventions that work.

Subject of Research: Aging immune system; immune response initiation models and modulation

Article Title: Bioengineering strategies to interrogate and modulate the aging immune system

Article References: Nikolich, J.Ž., Wolf, M.T., Pompano, R.R. et al. Bioengineering strategies to interrogate and modulate the aging immune system. Nat Aging (2026). https://doi.org/10.1038/s43587-026-01187-y

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s43587-026-01187-y

Glenview, Illinois—CHEST, the American College of Chest Physicians’ flagship journal portfolio, has reported a major milestone for its open-access publication CHEST® Critical Care: the journal has earned its first Journal Impact Factor of 2.7. Released annually by Clarivate through the Journal Citation Reports, the metric reflects the average number of citations received by articles published in a journal, serving as a widely used proxy for scholarly influence.

In practical terms, an Impact Factor offers more than prestige. It functions as a signal to authors, clinicians, and research teams that the work circulating in a journal is being engaged by the wider scientific and medical community—particularly important in time-sensitive domains like intensive care medicine, where findings can influence protocols and bedside decision-making.

Hayley Gershengorn, MD, FCCP, Editor in Chief of CHEST Critical Care, emphasized that the achievement is rooted in the ecosystem around the journal. Authors contribute original and reproducible studies; reviewers help refine rigor and clarity; editorial leadership maintains standards; and readers ensure the research travels beyond publication.

The journal was designed to accelerate dissemination of high-quality critical care research while keeping access frictionless. Because CHEST Critical Care is fully open access, its content can be read by practitioners, investigators, and policymakers worldwide without subscription barriers—an element that can broaden citation pathways and facilitate adoption of evidence-based practices.

Beyond original studies, the journal publishes a range of formats, including reviews and case reports, as well as “How I Do It” clinical education articles. This blend supports both scientific discovery and translational learning, which can be critical for managing complex syndromes such as sepsis, respiratory failure, and septic shock.

For biomedical audiences, open-access visibility plus peer-reviewed credibility creates a compelling combination: findings are discoverable, accessible, and citable. That coupling helps explain why emerging journals can gain momentum quickly when their content resonates with urgent clinical needs.

To follow updates across the CHEST journal ecosystem, readers can visit the CHEST website and track news via the journal’s social channels. The organization frames the Impact Factor as a validation of community effort—and as motivation to keep publishing research that improves outcomes in critical care.

Subject of Research: Critical care medicine; scholarly publishing metrics
Article Title: CHEST Critical Care Achieves First Journal Impact Factor of 2.7
News Publication Date: Not provided
Web References: https://www.chestnet.org/guidelines-and-topic-collections/publications ; https://www.twitter.com/journal_chest
References: Clarivate Journal Citation Reports (Journal Impact Factor methodology)
Image Credits: Not provided
Keywords: CHEST Critical Care, Journal Impact Factor, Clarivate, open access publishing, critical care medicine, citations, peer review, intensive care research